Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11782034 | 1.00 | SIGMAR1 (0.46) | SIGMAR1OPRD1KCNH2OPRM1PRCP | |
| SCHEMBL4363631 | 0.88 | OPRD1 (0.50) | SIGMAR1OPRD1KCNH2OPRM1PRCP | |
| SCHEMBL29705809 | 0.88 | OPRD1 (0.50) | SIGMAR1OPRD1KCNH2OPRM1PRCP | |
| SCHEMBL11686154 | 0.86 | PRCP (0.43) | SIGMAR1OPRD1KCNH2PRCP | |
| SCHEMBL11870107 | 0.86 | SIGMAR1 (0.43) | SIGMAR1OPRD1KCNH2PRCP | |
| SCHEMBL11853705 | 0.85 | SIGMAR1 (0.49) | SIGMAR1OPRD1KCNH2PRCP | |
| SCHEMBL11355116 | 0.80 | TMEM97 (0.42) | SIGMAR1OPRD1KCNH2OPRM1PRCP | |
| SCHEMBL11355120 | 0.80 | TMEM97 (0.42) | SIGMAR1OPRD1KCNH2OPRM1PRCP | |
| SCHEMBL11781458 | 0.80 | OPRD1 (0.46) | SIGMAR1OPRD1KCNH2PRCP | |
| SCHEMBL12175500 | 0.80 | PRCP (0.54) | SIGMAR1OPRD1KCNH2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | Sumitomo Pharma Co., Ltd. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4252846-A1 | REGULATOR FOR EXPRESSION AND/OR FUNCTION OF RPS25 GENE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-04 | — | — | EP | disclosed |
| CN-116507727-A | Modulators of expression and/or function of the RPS25 gene | 住友制药株式会社 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | RPS25, RPS26, RPS24 | SIGMAR1 3235/4885OPRD1 2013/4885KCNH2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.